HCA HCA Healthcare, Inc. Common Stock
HCA Healthcare, Inc. Common Stock Hakkında Wikipedia'dan şirket genel bakışı
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
Devamını oku
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was serving as chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
HCA Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
HCA Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Temettüler Temettü verimi, ödeme oranı, temettü geçmişi, 5 Yıllık CAGR
| Ex-tarihi | Miktar |
|---|---|
| 16 Haziran 2026 | $0,7800 |
| 17 Mart 2026 | $0,7800 |
| 15 Aralık 2025 | $0,7200 |
| 16 Eylül 2025 | $0,7200 |
| 16 Haziran 2025 | $0,7200 |
| 17 Mart 2025 | $0,7200 |
| 13 Aralık 2024 | $0,6600 |
| 16 Eylül 2024 | $0,6600 |
| 14 Haziran 2024 | $0,6600 |
| 14 Mart 2024 | $0,6600 |
| 13 Aralık 2023 | $0,6000 |
| 14 Eylül 2023 | $0,6000 |
| 15 Haziran 2023 | $0,6000 |
| 16 Mart 2023 | $0,6000 |
| 13 Aralık 2022 | $0,5600 |
| 15 Eylül 2022 | $0,5600 |
| 15 Haziran 2022 | $0,5600 |
| 16 Mart 2022 | $0,5600 |
| 13 Aralık 2021 | $0,4800 |
| 15 Eylül 2021 | $0,4800 |
HCA Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
- Güçlü Al 6 20,0%
- Al 11 36,7%
- Tut 12 40,0%
- Sat 1 3,3%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
21 analist · 2026-08-17Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $7.62 | $7.54 | 0.08% |
| 31 Mart 2026 | $7.15 | $7.21 | -0.06% |
| 31 Aralık 2025 | $8.14 | $7.53 | 0.61% |
| 30 Eylül 2025 | $6.96 | $5.77 | 1.2% |
| 30 Haziran 2025 | $6.83 | $6.31 | 0.52% |
| 31 Mart 2025 | $6.45 | $5.84 | 0.61% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | — |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | — |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | — |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | — |
| UHS | — | 9.4 | 9.7% | 8.6% | 21.4% | — |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | — |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | — |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | — |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 12
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
Bilanço 22
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
Nakit Akışı 17
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
Kârlılık 5
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
Likidite ve Solventlik 4
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
Verimlilik 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
Büyüme Oranları 10
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 17
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
Gelir Tablosu 12
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | -482,587,000 | 232,891,000 | 239,173,000 | 246,936,000 | -523,751,000 | 256,763,000 | 261,156,000 | 264,435,000 | -550,173,000 | 271,173,000 | 274,494,000 | 276,910,000 | -590,583,000 | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | -488,037,000 | 236,181,000 | 241,911,000 | 249,440,000 | -530,198,000 | 259,917,000 | 264,071,000 | 268,016,000 | -558,171,000 | 275,424,000 | 278,198,000 | 280,961,000 | -598,621,000 | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
Bilanço 20
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
Nakit Akışı 16
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
Kârlılık 5
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
Likidite ve Solventlik 4
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
Verimlilik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Değerleme (TTM) 14
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $77.11B | $75.20B | · | $73.57B | $71.91B | $70.64B | · | $68.53B | $66.91B | $65.00B | · | $62.64B | $61.24B | $60.33B | · | $60.01B | |
| Net Income TTM | $6.62B | $6.53B | · | $6.18B | $5.99B | $5.93B | · | $5.40B | $5.32B | $5.23B | · | $4.77B | $4.84B | $4.92B | · | $5.83B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.7 | 17.3 | · | 17.0 | 16.2 | 15.2 | · | 20.1 | 16.3 | 17.6 | · | 14.5 | 17.9 | 15.7 | · | 9.7 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.3 | 1.2 | · | 1.5 | 1.2 | 1.4 | · | 1.1 | 1.4 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| P / FCF | · | 117.7 | · | · | · | 127.2 | · | · | · | 65.0 | · | · | · | 120.1 | · | · | |
| EV / EBITDA | 135.0 | 154.7 | · | 152.3 | 149.4 | 148.2 | · | 170.5 | 150.6 | 159.4 | · | 136.0 | 158.5 | 146.5 | · | 118.7 | |
| EV / FCF | · | 160.7 | · | · | · | 193.1 | · | · | · | 93.8 | · | · | · | 182.8 | · | · | |
| EV / Revenue | 1.7 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Earnings Yield | 7.3% | 5.8% | · | 5.9% | 6.2% | 6.6% | · | 5.0% | 6.1% | 5.7% | · | 6.9% | 5.6% | 6.4% | · | 10.3% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| Net Gelir | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| Seyreltilmiş Hisse Başı Kâr | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| Cari Oran | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| Cari Oran | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
Son Haberler Bu şirketten bahseden son manşetler
- Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?
- Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027
- HCA Healthcare (HCA) Reports Q1 2026 Financial Growth With $19.1B in Revenue
- Perşembe Gününün Dikkat Çeken Opsiyon Faaliyetleri: HCA, HRTG, ZM
- HCA Healthcare (HCA) Finansman Stratejisi Genişliyor – İşte Nasıl
- HCA Sağlık, Tıbbi Bakım Talebi Sayesinde Çeyreklik Kâr Tahminlerini Aştı
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 1.491 dosya · $39.4B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 128 (-51 önceki Ç'ye göre) | 174 (+70 önceki Ç'ye göre) | 450 (-30 önceki Ç'ye göre) | 555 (-4 önceki Ç'ye göre) | +16.3M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6.118.113.464 | 13.104.814 | 15,52% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.954.150.533 | 10.141.708 | 10,03% | Hisse senetleri |
| Sanders Capital, LLC | $3.442.060.818 | 8.828.287 | 8,73% | Hisse senetleri |
| STATE STREET CORP | $2.912.102.056 | 7.469.035 | 7,39% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $1.750.298.867 | 4.489.212 | 4,44% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $1.225.259.672 | 3.159.159 | 3,11% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.057.704.509 | 2.712.828 | 2,68% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861.456.107 | 2.209.485 | 2,18% | Hisse senetleri |
| NORGES BANK | $836.457.140 | 2.145.367 | 2,12% | Hisse senetleri |
| Capital World Investors | $770.864.224 | 1.977.121 | 1,96% | Hisse senetleri |
| Capital International Investors | $747.403.041 | 1.916.947 | 1,90% | Hisse senetleri |
| Crake Asset Management LLP | $449.072.183 | 1.151.792 | 1,14% | Hisse senetleri |
| Metropolis Capital Ltd | $430.915.307 | 910.564 | 1,09% | Hisse senetleri |
| Darsana Capital Partners LP | $428.879.000 | 1.100.000 | 1,09% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414.533.777 | 1.063.207 | 1,05% | Hisse senetleri |
| Life Cycle Investment Partners Ltd | $355.737.196 | 912.404 | 0,90% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $339.685.814 | 871.235 | 0,86% | Hisse senetleri |
| FMR LLC | $325.199.295 | 834.080 | 0,82% | Hisse senetleri |
| BARCLAYS PLC | $299.888.573 | 769.162 | 0,76% | Hisse senetleri |
| LYRICAL ASSET MANAGEMENT LP | $255.015.742 | 654.071 | 0,65% | Hisse senetleri |
| BlackRock, Inc. | $240.062.291 | 615.718 | 0,61% | Hisse senetleri |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235.649.908 | 604.401 | 0,60% | Hisse senetleri |
| National Pension Service | $230.650.346 | 591.578 | 0,59% | Hisse senetleri |
| NORDEA INVESTMENT MANAGEMENT AB | $230.189.125 | 594.466 | 0,58% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $209.775.669 | 538.038 | 0,53% | Hisse senetleri |
| Gobi Capital LLC | $195.742.325 | 502.045 | 0,50% | Hisse senetleri |
| Cryder Capital Partners LLP | $194.561.738 | 499.017 | 0,49% | Hisse senetleri |
| Swiss National Bank | $172.097.446 | 441.400 | 0,44% | Hisse senetleri |
| AustralianSuper Pty Ltd | $159.635.782 | 409.438 | 0,40% | Hisse senetleri |
| Consulta Ltd | $155.956.000 | 400.000 | 0,40% | Hisse senetleri |
| LEE DANNER & BASS INC | $152.150.679 | 390.240 | 0,39% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $151.472.265 | 388.500 | 0,38% | Alım opsiyonu |
| Mitsubishi UFJ Asset Management Co., Ltd. | $147.943.761 | 379.450 | 0,38% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $139.697.405 | 358.300 | 0,35% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $136.962.509 | 351.285 | 0,35% | Hisse senetleri |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $134.838.505 | 288.820 | 0,34% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $134.459.788 | 284.126 | 0,34% | Hisse senetleri |
| Sumitomo Mitsui Trust Group, Inc. | $132.794.974 | 340.596 | 0,34% | Hisse senetleri |
| TD Asset Management Inc | $131.847.152 | 338.165 | 0,33% | Hisse senetleri |
| Legal & General Group Plc | $127.805.162 | 327.798 | 0,32% | Hisse senetleri |
| California Public Employees Retirement System | $124.133.958 | 318.382 | 0,31% | Hisse senetleri |
| LAZARD ASSET MANAGEMENT LLC | $120.619.879 | 309.369 | 0,31% | Hisse senetleri |
| JANE STREET GROUP, LLC | $119.540.274 | 306.600 | 0,30% | Alım opsiyonu |
| VANGUARD ASSET MANAGEMENT, Ltd | $116.069.863 | 297.699 | 0,29% | Hisse senetleri |
| CAPTRUST FINANCIAL ADVISORS | $114.741.071 | 294.291 | 0,29% | Hisse senetleri |
| ANTIPODES PARTNERS Ltd | $113.045.096 | 289.941 | 0,29% | Hisse senetleri |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $109.718.328 | 231.845 | 0,28% | Hisse senetleri |
| CITADEL ADVISORS LLC | $105.660.190 | 271.000 | 0,27% | Alım opsiyonu |
| RHUMBLINE ADVISERS | $97.580.413 | 250.277 | 0,25% | Hisse senetleri |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $97.026.076 | 248.855 | 0,25% | Hisse senetleri |
| MACKENZIE FINANCIAL CORP | $93.597.383 | 240.061 | 0,24% | Hisse senetleri |
| BloombergSen Inc. | $93.160.317 | 238.940 | 0,24% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92.247.974 | 236.600 | 0,23% | Satım opsiyonu |
| Brandywine Global Investment Management, LLC | $89.380.814 | 191.451 | 0,23% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $89.069.981 | 228.449 | 0,23% | Hisse senetleri |
| NEUBERGER BERMAN GROUP LLC | $85.926.216 | 220.386 | 0,22% | Hisse senetleri |
| MILFORD FUNDS LTD | $82.165.029 | 210.739 | 0,21% | Hisse senetleri |
| Bridgewater Associates, LP | $79.227.208 | 203.204 | 0,20% | Hisse senetleri |
| Prana Capital Management, LP | $75.552.494 | 193.779 | 0,19% | Hisse senetleri |
| DANSKE BANK A/S | $73.238.497 | 187.844 | 0,19% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $70.965.828 | 182.015 | 0,18% | Hisse senetleri |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $70.445.715 | 180.681 | 0,18% | Hisse senetleri |
| Quantinno Capital Management LP | $70.407.055 | 180.581 | 0,18% | Hisse senetleri |
| ARGENT CAPITAL MANAGEMENT LLC | $69.149.681 | 177.357 | 0,18% | Hisse senetleri |
| Retirement Systems of Alabama | $68.081.812 | 174.618 | 0,17% | Hisse senetleri |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $66.167.842 | 169.709 | 0,17% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $64.793.090 | 166.183 | 0,16% | Hisse senetleri |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $64.665.206 | 165.855 | 0,16% | Hisse senetleri |
| HSBC HOLDINGS PLC | $64.431.534 | 165.332 | 0,16% | Hisse senetleri |
| AVIVA PLC | $64.264.789 | 164.828 | 0,16% | Hisse senetleri |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $64.194.533 | 135.649 | 0,16% | Hisse senetleri |
| SEB Asset Management AB | $63.257.255 | 162.244 | 0,16% | Hisse senetleri |
| TODD ASSET MANAGEMENT LLC | $62.567.208 | 160.474 | 0,16% | Hisse senetleri |
| Swedbank AB | $62.528.998 | 160.376 | 0,16% | Hisse senetleri |
| W1M Investment Management Ltd | $61.247.490 | 143.647 | 0,16% | Hisse senetleri |
| HARRIS ASSOCIATES L P | $60.080.879 | 154.097 | 0,15% | Hisse senetleri |
| Ensign Peak Advisors, Inc | $58.372.381 | 149.715 | 0,15% | Hisse senetleri |
| NEW YORK STATE COMMON RETIREMENT FUND | $57.747.778 | 148.113 | 0,15% | Hisse senetleri |
| CITADEL ADVISORS LLC | $57.235.852 | 146.800 | 0,15% | Satım opsiyonu |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $57.160.993 | 146.800 | 0,14% | Hisse senetleri |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $56.512.217 | 144.944 | 0,14% | Hisse senetleri |
| Pictet Asset Management Holding SA | $52.147.803 | 133.739 | 0,13% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $50.752.761 | 130.172 | 0,13% | Hisse senetleri |
| Pentwater Capital Management LP | $50.685.700 | 130.000 | 0,13% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $50.554.307 | 129.663 | 0,13% | Hisse senetleri |
| APG Asset Management N.V. | $50.368.550 | 147.699 | 0,13% | Hisse senetleri |
| AMF Tjanstepension AB | $50.355.853 | 129.154 | 0,13% | Hisse senetleri |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $50.349.225 | 129.137 | 0,13% | Hisse senetleri |
| EQUITABLE TRUST CO | $49.147.974 | 126.056 | 0,12% | Hisse senetleri |
| ENVESTNET ASSET MANAGEMENT INC | $48.919.124 | 125.469 | 0,12% | Hisse senetleri |
| CANADA PENSION PLAN INVESTMENT BOARD | $48.197.812 | 123.619 | 0,12% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $47.460.140 | 121.727 | 0,12% | Hisse senetleri |
| OpenArc Corporate Advisory, LLC | $47.210.610 | 121.087 | 0,12% | Hisse senetleri |
| L1 Capital International Pty Ltd | $46.121.648 | 118.294 | 0,12% | Hisse senetleri |
| FIRST TRUST ADVISORS LP | $44.251.579 | 113.498 | 0,11% | Hisse senetleri |
| PFA Pension, Forsikringsaktieselskab | $44.046.098 | 112.971 | 0,11% | Hisse senetleri |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $43.830.264 | 112.417 | 0,11% | Hisse senetleri |
| EP Wealth Advisors, LLC | $43.287.826 | 111.026 | 0,11% | Hisse senetleri |
| WOLVERINE TRADING, LLC | $42.597.104 | 101.200 | 0,11% | Alım opsiyonu |
| MERCER GLOBAL ADVISORS INC /ADV | $42.302.070 | 108.497 | 0,11% | Hisse senetleri |
Şirket yöneticileri 91 içeriden öğrenenler · 54 yöneticiler · 31 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 10 Şubat 2026 F | 64.842 | 0 | 7 | $-21.483.290 |
| O'Boyle Michael P | President & CEO - Parallon | 26 Şubat 2013 A | 21.429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 07 Mayıs 2026 G | 46.576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 16 Şubat 2024 F | 22.251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 17 Kasım 2006 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 17 Kasım 2006 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 17 Kasım 2006 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 01 Temmuz 2005 F | 13.865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 12 Kasım 2024 M | 6.843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 31 Temmuz 2024 M | 27.008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 16 Şubat 2024 F | 17.936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 11 Kasım 2022 M | 202.443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 11 Kasım 2022 S | 30.807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 31 Aralık 2012 A | 335.657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 02 Kasım 2011 M | 144.714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 26 Temmuz 2006 A | 62.173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 27 Ekim 2005 A | 26.154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 31 Ekim 2004 D | 9.029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 07 Mayıs 2004 D | 24.177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 10 Şubat 2026 F | 23.062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 13 Şubat 2026 M | 8.853 | 0 | 2 | $-2.747.520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 11 Şubat 2026 S | 11.993 | 0 | 2 | $-4.126.932 |
| Christopher F. Wyatt | SVP & Controller | 11 Şubat 2026 S | 44.379 | 0 | 1 | $-2.020.000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 10 Şubat 2026 F | 10.407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 10 Şubat 2026 F | 32.080 | 0 | 1 | $-747.135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 13 Şubat 2025 F | 11.113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 14 Kasım 2024 S | 9.454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 12 Kasım 2024 M | 52.702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 05 Ağustos 2024 G | 18.526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 29 Temmuz 2024 S | 3.510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 25 Temmuz 2024 S | 17.755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 09 Mayıs 2024 S | 5.185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 18 Mart 2024 M | 1.576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 12 Nisan 2023 M | 24.643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 09 Kasım 2021 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 05 Mayıs 2021 S | 50.062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 18 Şubat 2021 F | 5.578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 18 Şubat 2021 F | 10.122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 01 Mayıs 2019 A | 194.145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 25 Şubat 2019 M | 84.157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 25 Şubat 2019 M | 881.823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 25 Şubat 2018 M | 7.003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 25 Şubat 2018 M | 35.546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 25 Şubat 2018 M | 65.199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 23 Mayıs 2017 M | 26.378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 07 Kasım 2016 M | 110.167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 25 Şubat 2016 A | 51.965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 16 Mayıs 2012 M | 299.030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 06 Ekim 2009 A | 188.340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 27 Şubat 2009 M | 13.092 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 4 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 10 Şubat 2026 | 31,60% | İlk başvuru | — | SEC |
| 22 Kasım 2006 | — | İlk başvuru | — | SEC | |
| Merrill Lynch Bank USA | 11 Eylül 2006 | — | İlk başvuru | — | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 04 Ağustos 2006 | — | İlk başvuru | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 207 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IHF · iShares Trust | 4,67% | 141.320 SH | 08 Ağustos 2026 | Günlük |
| BUL · Pacer Funds Trust | 3,91% | 11.437 NS | 30 Nisan 2026 | N-PORT |
| YALL · Tidal Trust I | 3,61% | 9.261 NS | 31 Mayıs 2026 | N-PORT |
| BWTG · ETF Opportunities Trust | 3,02% | 1.646 NS | 31 Mayıs 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2,32% | 99.335 SH | 08 Ağustos 2026 | Günlük |
| ABIG · EA Series Trust | 2,00% | 2.938 NS | 29 Mayıs 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,99% | 39.985 NS | 30 Nisan 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,67% | 31.685 SH | 08 Ağustos 2026 | Günlük |
| COWZ · Pacer Funds Trust | 1,64% | 688.264 NS | 30 Nisan 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 1,64% | 1.762 NS | 30 Nisan 2026 | N-PORT |
| FEGE · RBB Fund Trust | 1,46% | 74.706 NS | 31 Mayıs 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,39% | 60.385 SH | 08 Ağustos 2026 | Günlük |
| RPG · Invesco Exchange-Traded Fund Trust | 1,30% | 63.448 SH | 08 Ağustos 2026 | Günlük |
| TMFE · RBB Fund, Inc. | 1,29% | 2.892 NS | 31 Mayıs 2026 | N-PORT |
| AMID · EA Series Trust | 1,23% | 3.402 NS | 29 Mayıs 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,15% | 7.180 NS | 30 Nisan 2026 | N-PORT |
| FMAG · FIDELITY COVINGTON TRUST | 1,12% | 6.544 NS | 30 Nisan 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,12% | 73.639 NS | 30 Nisan 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,10% | 4.883 NS | 30 Nisan 2026 | N-PORT |
| IYH · iShares Trust | 0,99% | 89.420 SH | 08 Ağustos 2026 | Günlük |
| NEAR · iShares U.S. ETF Trust | 0,99% | 48.109.000 SH | 08 Ağustos 2026 | Günlük |
| CURE · Direxion Shares ETF Trust | 0,98% | 3.122 NS | 30 Nisan 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,90% | 470.451 SH | 08 Ağustos 2026 | Günlük |
| NFRA · FlexShares Trust | 0,88% | 62.176 NS | 30 Nisan 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0,87% | 5.693 NS | 30 Nisan 2026 | N-PORT |
| RXL · ProShares Trust | 0,86% | 1.632 NS | 31 Mayıs 2026 | N-PORT |
| DIVB · iShares Trust | 0,85% | 36.806 SH | 08 Ağustos 2026 | Günlük |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,82% | 24.078.000 | 08 Ağustos 2026 | Günlük |
| LSEQ · Harbor ETF Trust | 0,81% | 285 NS | 30 Nisan 2026 | N-PORT |
| IXJ · iShares Trust | 0,80% | 81.465 SH | 08 Ağustos 2026 | Günlük |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,76% | 26.493.000 | 08 Ağustos 2026 | Günlük |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,74% | 2.335 SH | 08 Ağustos 2026 | Günlük |
| FTC · First Trust Exchange-Traded AlphaDE… | 0,73% | 21.329 NS | 30 Nisan 2026 | N-PORT |
| RFFC · ALPS ETF Trust | 0,68% | 533 NS | 31 Mayıs 2026 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,68% | 2.698 NS | 30 Nisan 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,67% | 12.075 SH | 08 Ağustos 2026 | Günlük |
| VCEB · VANGUARD WORLD FUND | 0,62% | 8.146.000 PA | 08 Ağustos 2026 | Günlük |
| FDMO · FIDELITY COVINGTON TRUST | 0,61% | 11.771 NS | 30 Nisan 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0,58% | 72.768 NS | 30 Nisan 2026 | N-PORT |
| AFLG · First Trust Exchange-Traded Fund VI… | 0,56% | 9.664 NS | 31 Mayıs 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,55% | 11.876 SH | 08 Ağustos 2026 | Günlük |
| VLLU · Harbor ETF Trust | 0,54% | 54 NS | 30 Nisan 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,53% | 7.404 NS | 30 Nisan 2026 | N-PORT |
| WLDR · Two Roads Shared Trust | 0,51% | 844 NS | 30 Nisan 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 0,50% | 4.620 NS | 31 Mayıs 2026 | N-PORT |
| AKAF · ETF Series Solutions | 0,50% | 39 NS | 31 Mayıs 2026 | N-PORT |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,50% | 22.679.000 | 08 Ağustos 2026 | Günlük |
| ROUS · Lattice Strategies Trust | 0,47% | 6.388 NS | 30 Nisan 2026 | N-PORT |
| VCLT · VANGUARD SCOTTSDALE FUNDS | 0,46% | 54.218.000 PA | 08 Ağustos 2026 | Günlük |
| CGGR · Capital Group Growth ETF | 0,45% | 290.273 NS | 31 Mayıs 2026 | N-PORT |